Hyalex Orthopaedics raised US $16MM in a Series A financing. The company is developing HYALEX™ synthetic polymer that is designed to mimic hyaline cartilage, to potentially replace only diseased areas of joints while sparing healthy bone.
HYALEX was developed with technology licensed from Stanford University. The finacing was led by Canaan Partners, with participation from Osage University Partners and Johnson & Johnson Innovation.
Source: Hyalex Orthopaedics
Hyalex Orthopaedics raised US $16MM in a Series A financing. The company is developing HYALEX™ synthetic polymer that is designed to mimic hyaline cartilage, to potentially replace only diseased areas of joints while sparing healthy bone.
HYALEX was developed with technology licensed from Stanford University. The finacing was led by...
Hyalex Orthopaedics raised US $16MM in a Series A financing. The company is developing HYALEX™ synthetic polymer that is designed to mimic hyaline cartilage, to potentially replace only diseased areas of joints while sparing healthy bone.
HYALEX was developed with technology licensed from Stanford University. The finacing was led by Canaan Partners, with participation from Osage University Partners and Johnson & Johnson Innovation.
Source: Hyalex Orthopaedics
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





